StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

HAEBearishEarningsnews
High materiality7/10

These Analysts Slash Their Forecasts On Haemonetics After Q1 Results

Aug 8, 2025, 9:33 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Despite strong earnings, downgrades and lowered price targets indicate caution among analysts. Historical trends show that downgrades often lead to short-term price declines.

AI summary

What happened, with direct paths to the underlying reporting

HAE reported Q1 earnings of $1.10, beating estimates. Quarterly sales reached $321.394 million, exceeding expectations. FY2026 EPS guidance reaffirmed between $4.70 and $5.00. JP Morgan downgraded HAE from Overweight to Neutral. Other analysts maintained rating but lowered price targets.

  • HAE reported Q1 earnings of $1.10, beating estimates.
  • Quarterly sales reached $321.394 million, exceeding expectations.
  • FY2026 EPS guidance reaffirmed between $4.70 and $5.00.
  • JP Morgan downgraded HAE from Overweight to Neutral.
  • Other analysts maintained rating but lowered price targets.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.